New drug duo aims to shrink lung tumors in First-Line trial
NCT ID NCT07353957
First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 5 times
Summary
This phase 2 trial tests whether adding petosemtamab to the standard immunotherapy pembrolizumab can shrink tumors in adults with metastatic non-small cell lung cancer. About 180 participants will receive the combination as their first treatment. The study focuses on how many patients respond and how long the benefit lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Petosemtamab and pembrolizumab
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with advanced non-small cell lung cancer, potentially improving tumor shrinkage rates.
- What could go wrong
- This is an early-phase trial with only 180 participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER - NON SMALL CELL NON-SQUAMOUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Australia Site 1
Frankston, Victoria, 3199, Australia
-
CHU Brest Hopital la Cavale Blanche
Brest, 29609, France
-
Centre Hospitalier Intercommunal de Creteil (CHIC)
Créteil, 94000, France
-
Chungbuk National University Hospital
Cheongju-si, 28645, South Korea
-
Clinica Universidad de Navarra - Pamplona
Pamplona, 31008, Spain
-
Flinders Medical Centre
Bedford Park, South Australia, 5042, Australia
-
Florida Cancer Specialists - North
St. Petersburg, Florida, 33701-4553, United States
-
HC Hospitales SL
Marbella, 29660, Spain
-
Hopital Nord Laennec
Nantes, 44093, France
-
Hospital Alvaro Cunqueiro
Vigo, 36312, Spain
-
Hospital Quironsalud Malaga
Málaga, 29004, Spain
-
Hospital Universitario de Navarra
Pamplona, 31008, Spain
-
ICM - Montpellier Cancer Institute
Montpellier, 34298, France
-
Kyungpook National University Chilgok Hospital
Daegu, 41404, South Korea
-
Leiden University Medical Center
Leiden, 2333, Netherlands
-
Memorial Sloan Kettering Cancer Center
Long Island City, New York, 11101, United States
-
START - Rioja
Logroño, 26006, Spain
-
Severance Hospital - Yonsei University Health System
Seoul, 3722, South Korea
-
Tennessee Site 1
Nashville, Tennessee, 37209, United States
-
Tennessee Site 2
Chattanooga, Tennessee, 37403, United States
-
The Catholic University of Korea, St. Vincents Hospital
Suwon, 16247, South Korea
-
Universita degli Studi di Firenze - Azienda Ospedaliero-Universitaria Careggi
Florence, 50134, Italy
-
Virginia Site 1
Fairfax, Virginia, 22031, United States
-
Virginia Site 2
Blacksburg, Virginia, 24060, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.